Studies link GLP-1 medicines, including tirzepatide, with fewer severe infections and lower tuberculosis risk, though researchers caution that the observational evidence does not prove prevention.
For years, medicines that act on gut hormones were viewed mainly as tools for controlling blood sugar. Then GLP-1 receptor agonists, along with related incretin drugs, came to be seen as powerful treatments for obesity. Now a growing body of research suggests their reach may be wider still, extending beyond weight and glucose control into inflammation, immune function and perhaps even resistance to serious infection.
That broader possibility sits at the heart of a recent discussion in Ta Nea by Georgios P. Chrousos, who argues that metabolic health and immunity cannot be separated. Obesity is not just excess fat storage, he writes, but a state of chronic low-grade inflammation and vascular stress. Diabetes adds another layer of risk because high blood sugar can weaken the function of key immune cells, delay healing and encourage microbial growth.
Recent observational studies are beginning to give that theory clinical shape. Harvard Health reported on a large BMJ study of 52,971 adults over 40 with type 2 diabetes and established atherosclerotic cardiovascular disease. In that analysis, 35,353 people started tirzepatide and 17,618 received sitagliptin. After one year, the combined risk of heart attack, stroke or death was 2.9% in the tirzepatide group, compared with 4.4% in the sitagliptin group, a relative reduction of 32%.
The most striking finding, however, was not cardiovascular. According to Harvard Health’s summary of the BMJ paper, hospital-treated infections were 36% less common among patients taking tirzepatide, while deaths linked to infection fell by 60%. Even urinary infections were less frequent. In absolute terms, the study suggested that treating 48 patients for a year might prevent one hospital admission for a severe infection. The result does not prove causation, but it raises a serious scientific question.
A second, much larger electronic health-record analysis points in the same direction. Drawing on data from 143 healthcare organisations and more than seven million people with type 2 diabetes, researchers compared users of GLP-1 drugs with patients taking sulfonylureas, metformin, DPP-4 inhibitors or SGLT2 inhibitors. The focus was tuberculosis, one of the world’s leading infectious killers. In that study, GLP-1 drugs were associated with a substantially lower relative risk of tuberculosis than sulfonylureas, metformin and DPP-4 inhibitors, with a smaller but still significant reduction versus SGLT2 inhibitors.
The tuberculosis finding matters because diabetes itself is a major risk factor for the disease. People with diabetes face roughly two to three times the risk of active tuberculosis, and the combination of chronic inflammation, vascular damage and poor glucose control can weaken cellular immunity. The newer data do not show that GLP-1 medicines prevent tuberculosis, but they do suggest that these drugs may influence the body’s defences in ways that go beyond glucose lowering and weight loss.
That idea is supported by mechanistic research. Reviews in ScienceDirect and the National Library of Medicine have described anti-inflammatory and immunomodulatory effects linked to GLP-1 therapies, including influences on neutrophils, macrophages, T cells, the NLRP3 inflammasome and endothelial function. One recent review also notes that some anti-inflammatory benefits may arise independently of metabolic change, which would help explain why some effects appear early, before major weight loss has occurred.
Still, caution is essential. Both the BMJ analysis and the tuberculosis study were observational rather than randomised trials, so they can show association but not proof. There may be differences between patient groups that remain unmeasured, including prior infection, social conditions, medication adherence and the severity of illness. For that reason, the findings should not be taken to mean that GLP-1 drugs prevent or treat infection, and they certainly do not replace vaccination, screening, tuberculosis control measures or standard antimicrobial therapy.
Even so, the emerging pattern is important. The evidence suggests that diabetes, obesity, cardiovascular disease and infection vulnerability may be different expressions of a shared disturbance in the body’s regulatory balance. In that sense, GLP-1 medicines may be doing more than helping patients lose weight or lower blood sugar. They may also be helping to restore a broader state of metabolic and immune stability, with benefits that reach well beyond the original prescription.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
